期刊文献+

依那普利与硝苯地平控释片联用对高血压伴左室肥厚的疗效观察 被引量:2

THE CLINICAL EFFICACY OF COMBINATION THERAPY WITH ENALAPRIL AND NIFEDIPINE CONTROLLED ON THE ESSENTIAL HYPERTENSION WITH LEFT VENTRICULAR HYPERTROPHY
下载PDF
导出
摘要 目的 :观察依那普利与硝苯地平控释片联用对原发性高血压 ( EH)伴左室肥厚 ( LVH)的疗效。方法 :将 EH伴 LVH患者 1 60例随机分为 A、B两组 ,A组 82例 ,单用依那普利 ,B组 78例 ,依那普利与硝苯地平控释片联用。观察两组在治疗前和治疗 6个月后及两组间血压与 LVH指标的变化。结果 :治疗 6个月后两组血压均较治疗前明显下降 ( P<0 .0 1 )且两组间降压幅度无显著性差异 ( P>0 .0 5 ) ;两组左室重量指数较治疗前均明显降低 ,A组 ( P>0 .0 5 )较 B组明显 ( P<0 .0 5 )。结论 :两药合用对 Objective:To observe the clinical efficacy of enalapril combined with nifedipine controlled for reducing left ventricular hypertrophy in patients with essential hypertension (EH).Methods:One hundred and sixty patients with EH were randomly divided into two groups,group A and group B.Group A served as enalapril treatment group (82 cases).Group B served as enalapril plus nifedipine controlled treatment group (78 cases).The indexes of observation included changes of blood pressure and left ventricular hypertrophy after 6 months treatment in both groups.Results:It was found that blood pressure was significantly decreased in both groups after 6 months treatment ( P <0 01),but no difference was found in the level of blood pressure reduction between the two groups( P >0 05).Index of left ventricular mass was reduced significantly in both groups( P <0 01) and this effect was more obvious in group B than in group A( P <0 05).Conclusion:Enalapril combined with nifedipine controlled may cause additive effect in the reduction of left ventricular hypertrophy.
出处 《滨州医学院学报》 2003年第6期404-405,共2页 Journal of Binzhou Medical University
关键词 原发性高血压 左室肥厚 依那普利 硝苯地平控释片 hypertension left ventricular hypertrophy enalapril nifedipine controlled
  • 相关文献

参考文献1

共引文献68

同被引文献25

  • 1王登平.硝苯地平控释片治疗原发性高血压疗效观察[J].现代医药卫生,2006,22(20):3101-3102. 被引量:2
  • 2刘桂莲,于春梅.依那普利治疗高血压病100例疗效观察[J].吉林医学,2006,27(1):40-40. 被引量:5
  • 3刘铁有,王文斌,迟永前,谢玉霞,杨锦华,董树.硝苯吡啶与卡托普利联用逆转左心室肥厚的临床观察[J].齐齐哈尔医学院学报,1996,17(3):178-179. 被引量:1
  • 4李燕.依那普利和硝苯地平联用逆转原发性高血压左心室肥厚的临床观察[J].中国误诊学杂志,2007,7(16):3724-3724. 被引量:5
  • 5Katholi RE,Couri DM. Left ventricular hypertrophy:major risk factor in patients with hypertension:update and practical clinical applications[J].Int J Hypertens,2011,(06):1-10.
  • 6Schmieder RE,Schlaich MP,Klingbeil AU. Update on reversal of leh ventricular hypertrophy in essential hypertension (a metaanalysis of all randomized double-blind studies until December 1996)[J].Nephrology Dialysis Transplantation,1998,(03):564-569.
  • 7Mancia G,Laurent S,Agabiti-Rosei E. Reappraisal of European guidelines on hypertension management:a European Society of Hypertension Task Force document[J].I Hypertens,2009,(11):2121-2158.
  • 8Weder AB. The Avoiding Cardiovascular events through COMbination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial:a comparison of first-line combination therapies[J].Expert Op in Pharmacother,2005,(02):275-281.
  • 9Dahlof B,Sever PS,Pouher NR. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required,in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA):a multicentre randomised controlled trial[J].The Lancet,2005,(9489):895-906.
  • 10Cuspidi C,Sala C,Zanchetti A. Management of hypertension in patients with left ventricular hypertrophy[J].Current Hypertension Reports,2007,(06):498-505.

引证文献2

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部